Leap Therapeutics Inc (LPTX)
3.22
+0.05
(+1.58%)
USD |
NASDAQ |
Apr 26, 16:00
3.22
0.00 (0.00%)
After-Hours: 17:04
Leap Therapeutics Research and Development Expense (Quarterly): 11.68M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.68M |
| September 30, 2023 | 11.50M |
| June 30, 2023 | 11.10M |
| March 31, 2023 | 38.94M |
| December 31, 2022 | 11.03M |
| September 30, 2022 | 12.10M |
| June 30, 2022 | 14.04M |
| March 31, 2022 | 7.784M |
| December 31, 2021 | 8.07M |
| September 30, 2021 | 10.08M |
| June 30, 2021 | 7.206M |
| March 31, 2021 | 6.807M |
| December 31, 2020 | 5.101M |
| September 30, 2020 | 5.369M |
| June 30, 2020 | 5.35M |
| March 31, 2020 | 4.603M |
| December 31, 2019 | 5.668M |
| September 30, 2019 | 5.772M |
| June 30, 2019 | 6.136M |
| March 31, 2019 | 6.79M |
| December 31, 2018 | 6.908M |
| September 30, 2018 | 6.457M |
| Date | Value |
|---|---|
| June 30, 2018 | 4.234M |
| March 31, 2018 | 4.231M |
| December 31, 2017 | 4.416M |
| September 30, 2017 | 6.802M |
| June 30, 2017 | 4.881M |
| March 31, 2017 | 6.404M |
| December 31, 2016 | 7.422M |
| September 30, 2016 | 5.659M |
| June 30, 2016 | 6.124M |
| March 31, 2016 | 4.087M |
| December 31, 2015 | -3.846M |
| September 30, 2015 | 4.186M |
| June 30, 2015 | 4.82M |
| March 31, 2015 | 5.251M |
| December 31, 2014 | 5.679M |
| September 30, 2014 | 3.946M |
| June 30, 2014 | 3.22M |
| March 31, 2014 | 2.697M |
| December 31, 2013 | 3.02M |
| September 30, 2013 | 2.446M |
| June 30, 2013 | 1.759M |
| March 31, 2013 | 1.95M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.603M
Minimum
Mar 2020
38.94M
Maximum
Mar 2023
9.914M
Average
7.784M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Cutera Inc | 4.592M |
| OrthoPediatrics Corp | 2.747M |
| AIM ImmunoTech Inc | 3.20M |
| Protalix BioTherapeutics Inc | 3.102M |
| Armata Pharmaceuticals Inc | 7.928M |